CF PharmTech has raised $65M in a Series D financing with a future Industry Investment Fund, a private equity fund managed by SDIC Fund Management Corporation Limited, led the financing along with other prestigious healthcare investment groups in China.
CF PharmTech is focused on the development, manufacturing and commercialization of high-quality inhalation products for the global market. Since its inception, CF PharmTech has established a research and manufacturing facilities for its product development. The company said that this new round of investment will not only expedite the submission of its product pipeline to meet regulatory approvals in China and abroad, but also expand its CDMO service to international clients.
Hai Lu, Managing Director of SDIC Fund Management, said: “Drug delivery via pulmonary route bears significant technical challenges and it takes extraordinary effort to bring inhalation products to the market. CF PharmTech’s high caliber team has proved their ability to attract top industry talents to develop inhalation products for the global market. We are confident that they will achieve their business mission in the near future.”
CF PharmTech, headquartered in Suzhou, China, develops metered dose inhaler, inhalation powder, nasal spray and blow-fill-seal products. It has established high-quality research and manufacturing environments to be compliant with US, EU and Chinese regulations. CF PharmTech aims to provide quality and cost-effective inhalation products for domestic market, and seeks strategic partnerships to co-develop and commercialize its products globally.